Effect of DASH Diet and Progressive Muscle Relaxation on Cardiovascular Risks in Postmenopausal Women
Launched by CAIRO UNIVERSITY · Sep 13, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how a special diet known as the DASH diet, along with a technique called Progressive Muscle Relaxation, can help lower heart-related risks in postmenopausal women. The DASH diet focuses on eating healthy foods like fruits, vegetables, whole grains, and lean proteins, while Progressive Muscle Relaxation is a way to reduce stress by tensing and then relaxing different muscle groups in the body. The goal is to see if these two approaches can improve heart health for women aged 50 to 60 who are dealing with high blood pressure after menopause.
To participate in this study, women need to be between 50 and 60 years old, have a body mass index (BMI) between 30 and 35, and have been diagnosed with high blood pressure for at least a year after menopause. They should also feel a certain level of stress, as measured by a specific scale. However, women with very high blood pressure or other serious health issues related to their heart or kidneys, or those taking certain medications, will not be eligible. Participants can expect to learn more about managing their health through diet and relaxation techniques while contributing to important research that could benefit others in their situation.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • The participant's ages will be ranged from 50- 60 years old.
- • Their body mass index will be ranged from 30-35 kg/m2.
- • All women are hypertensive at least one year postmenopause.
- • Their scores in perceived stress scale will be ranged from 14-40.
- Exclusion Criteria:
- • Women with systolic blood pressure (SBP) \>160 mmHg or diastolic blood pressure (DBP) \>100mmHg.
- • Women who have other known causes of hypertension, such as renal diseases.
- • Women who are using sedatives or tranquilizer or antidepressant drugs.
About Cairo University
Cairo University, a premier institution in Egypt, is dedicated to advancing medical research and education through innovative clinical trials. With a strong emphasis on improving healthcare outcomes, the university collaborates with various stakeholders to conduct rigorous scientific studies that address critical health challenges. Leveraging its extensive resources and expert faculty, Cairo University aims to contribute valuable insights to the medical community and enhance patient care both locally and globally. Through its commitment to ethical research practices and excellence, the university plays a pivotal role in shaping the future of healthcare in the region.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Suez, , Egypt
Patients applied
Trial Officials
Mohamed Awad, professor
Study Director
Cairo University
Heba Abdel Halim, PHD
Study Director
National Institute of Nutrition
Hala Emara, professor
Study Chair
Cairo University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported